CHICAGO and FORT WORTH, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the closing of its $17.25 million underwritten public offering of... Read More

CHICAGO and FORT WORTH, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that it has priced an underwritten public offering of 2,142,858 shares... Read More

CHICAGO and FORT WORTH, Texas, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that it intends to offer and sell shares of its common stock in an... Read More

Phase 2 study showed a doubling of the survival rate of metastatic pancreatic cancer patients at Year 1, an unprecedented outcome Technology is seen as transformative in increasing the effectiveness of treatment for a wide range of cancers CHICAGO, IL AND FORT WORTH, TX / ACCESS Newswire / August 25, 2025 / Vexing challenges await cancer researchers every day -- not just in finding new molecules -- but now, increasingly, in... Read More

Clinical Trial Study to be Conducted at UPMC Hillman Cancer to Evaluate Novel Combination as Frontline Therapy CHICAGO and FORT WORTH, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase... Read More

Announces Completion of Phase 1 Study of Elraglusib in Pediatric Patients Prolonged and Durable Complete Responses (CRs) Observed in Two of Ten Refractory Ewing Sarcoma Patients Two Additional Patients Had Durable Stable Disease in Notoriously Difficult-to-Treat Cancer Confirmed Partial Response (PR) in a patient with a desmoplastic small-round-cell tumor (DSRCT) Company Initiating Planning of Phase 2 Trial of Elraglusib in... Read More

Near doubling of 1-year overall survival (OS), increased median OS of 4 months (12.5 vs 8.5 months), and 43% reduction in risk of death in patients treated with at least one cycle (4 weeks) of elraglusib plus gemcitabine/nab-paclitaxel (GnP) vs GnP alone Patients with liver metastases experienced a 2.5x improvement in 1-year OS with a 38% reduction in risk of death when treated with elraglusib plus GnP CHICAGO and FORT... Read More

Phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic pancreatic cancer (mPDAC) treated with elraglusib CHICAGO and FORT WORTH, Texas, June 20, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers... Read More

Inclusion reflects continued growth and momentum in the company’s mission to transform the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) CHICAGO and FORT WORTH, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers... Read More

Expert Insights on Clinical Relevance and Scientific Rationale The replay of the event is available on the Investor Relations section of the Actuate website CHICAGO and FORT WORTH, Texas, June 02, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat... Read More

Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1 months vs 7.2 months; log-rank p=0.01) in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving elraglusib/GnP Risk of death was reduced by 37% (HR=0.63) in patients treated with elraglusib/GnP Data featured as an oral presentation at the... Read More

Phase 2 (Actuate-1801 Part 3B) trial topline results meet primary endpoint of improved survival in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) Oral presentation at the American Society of Clinical Oncology (ASCO) annual meeting to highlight statistically significant improvement in median overall survival and 1-year survival rate in patients treated with the combination of elraglusib... Read More

Fireside discussion to explore clinical impact of the topline Phase 2 data in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) to be presented at ASCO In-person event and virtual webcast to be held on Saturday, May 31, 2025, at 6:30 pm CDT CHICAGO and FORT WORTH, Texas, May 07, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical... Read More

Topline data shows statistically significant improvement in overall survival in elraglusib plus GnP combination arm versus GnP control arm Elraglusib/GnP combination arm demonstrated substantial improvement in median overall survival since the last data analysis Clinical trial meets primary endpoint for overall survival and confirms significant 1-year survival rate Elraglusib/GnP combination arm demonstrated a favorable... Read More

CHICAGO and FORT WORTH, Texas, April 30, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Daniel Schmitt, President & Chief Executive Officer of Actuate... Read More

Oral presentation at ASCO to highlight topline Phase 2 data of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) CHICAGO and FORT WORTH, Texas, April 23, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the... Read More

CHICAGO and FORT WORTH, Texas, April 17, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that data on elraglusib in advanced salivary gland carcinoma will be... Read More

Initial Data from this Phase 2 Trial Demonstrates Early Evidence of Clinical Activity of Elraglusib (9-ING-41) in Combination with FOLFIRINOX and Losartan in Untreated Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) The Final Results from the Trial are Anticipated in 2026 CHICAGO and FORT WORTH, Texas, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a... Read More

CHICAGO and FORT WORTH, Texas, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Daniel Schmitt, President & Chief Executive Officer of Actuate... Read More

CHICAGO and FORT WORTH, Texas, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc . (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that the European Medicines Agency (EMA) has granted Orphan Medicinal... Read More

Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall Survival Doubling of 1 Year Survival Rate and 37% Reduction in Risk of Death Two Month (29%) Increase in Median Overall Survival Multiple Patients with Complete Responses (CRs) and/or Partial Response (PR) with 100% Reduction in Target Lesions Elraglusib in Combination with GnP Demonstrated a Favorable Risk-Benefit Profile Trial... Read More

CHICAGO and FORT WORTH, Texas, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers announced today that the Company will be added to the Russell 2000 ® Index as part of the planned fourth quarter IPO additions effective after the U.S... Read More

Ewing Sarcoma is a Highly Metastatic Form of Sarcoma and the Second Most Prevalent Primary Malignant Tumor in Children and Adolescents Ongoing Enrollment in Phase 1/2 Trial of Elraglusib in Relapsed/Refractory Ewing Sarcoma with Topline Phase 1 Data Expected in 2H 2025 Rare Pediatric Disease Designation Provides Eligibility for Elraglusib to Receive a Priority Review Voucher (PRV) Upon Marketing Approval that can be either... Read More

Companies will discuss how Lantern’s AI platform is being leveraged for the identification and development of enrichment biomarkers for Actuate’s lead investigational drug product, elraglusib CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of... Read More

New Mechanistic Insights Underscore Multiple Potential Roles for Elraglusib as an Immune Modulator in the treatment of Neuroblastoma Study Illustrates Potential to Activate the Immune System Even in Cancers That Have Not Previously Responded to Checkpoint Inhibitors CHICAGO and FORT WORTH, Texas, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage... Read More

Preclinical Study Highlight the Potential of Elraglusib in Overcoming FOLFIRINOX-induced Chemoresistance Through Downregulation of Epithelial to Mesenchymal Transition (EMT) Initial Data Demonstrates Early Evidence of Increased Clinical Activity of Combining FOLFIRINOX with Elraglusib and Losartan in Patients with Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Deep, Durable Responses Observed in 3/6 patients... Read More

Elraglusib is a Class-Leading GSK-3β Inhibitor with a Novel, Multimodal Mechanism of Action in Multiple Refractory Cancer Trials Orphan Drug Designation in Soft Tissue Sarcomas Expands Company’s Potential to Address Cancers with High Unmet Medical Need CHICAGO and FORT WORTH, Texas, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical... Read More

Elraglusib Demonstrated Anti-Tumor Activity with Two Ongoing Durable Complete Responses and ~62% Disease Control Rate in First 8 Patients with Relapsed/Refractory Ewing and Ewing-related Sarcomas Enrollment Ongoing with Topline Data Anticipated in 1H 2025 CHICAGO and FORT WORTH, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) – Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical... Read More

CHICAGO and FORT WORTH, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, including pancreatic cancer and Ewing sarcoma, through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that it will present... Read More

CHICAGO and FORT WORTH, Texas, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Daniel Schmitt, President & Chief Executive Office will ring the... Read More

CHICAGO and FORT WORTH, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Nasdaq: ACTU) (the “Company”) , a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers, announced today the closing of its previously announced initial public offering of 2,800,000 shares of its common stock, at a price of $8.00 per share to the public... Read More

CHICAGO and FORT WORTH, Texas, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Nasdaq: ACTU) (the “Company”) , a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers, announced today the pricing of its initial public offering of 2,800,000 shares of its common stock, at a price of $8.00 per share to the public for a total of... Read More